By IDSE News Staff
A single dose of the Imvanex (Jynneos in the United States) vaccine provides protection against mpox with 84% effectiveness. For people living with HIV, however, a single dose of the vaccine fails to offer sufficient protection.
All at-risk groups, and people with HIV in particular, should therefore receive the second dose of the vaccine as recommended, according to a study done by researchers at Berlin Institute of Health at Charité (BIH) (Lancet Infect Dis 2025; doi: 10.1016/S1473-3099(25)00082-9 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00082-9/fulltext).